Concepedia

Erica C. Nakajima

EC

Statistics

Publications

7

Citations

556

H-Index

7

Active since

2014

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Johns Hopkins University

Johns Hopkins Medicine

Erica C. Nakajima is an author at United States Food and Drug Administration specializing in lung cancer, medicine, and oncology.

ORCID

Top concepts

Publications per year

2014–2022

7

Publications

7

FDA Approval Summary: Sotorasib for <i>KRAS G12C</i> -Mutated Metastatic NSCLC

Erica C. Nakajima, Nicole Drezner, Xiaoxue Li et al. · Clinical Cancer Research · 2021 · 293 citations · Full text

Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.

Oladimeji Akinboro, Jonathon Vallejo, Erica C. Nakajima et al. · Journal of Clinical Oncology · 2022 · 77 citations

Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies

Xuguang Chen, Khadija Sheikh, Erica C. Nakajima et al. · The Oncologist · 2021 · 62 citations · Full text

Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.

Erica C. Nakajima, Yi Ren, Jonathon Vallejo et al. · Journal of Clinical Oncology · 2022 · 54 citations

, , +15

Quantifying Metabolic Heterogeneity in Head and Neck Tumors in Real Time: 2-DG Uptake Is Highest in Hypoxic Tumor Regions

Erica C. Nakajima, Charles M. Laymon, Matthew J. Oborski et al. · PLoS ONE · 2014 · 31 citations · Full text

1–5 of 7